pI: 6.4946 |
Length (AA): 296 |
MW (Da): 32508 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There is 1 model calculated for this protein. More info on
this model, including the
model itself is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
5 | 294 | 2p18 (A) | 6 | 293 | 54.00 | 0 | 1 | 1.70053 | -1.42 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_127291)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G31350 | Hydroxyacylglutathione hydrolase 2 |
Arabidopsis thaliana | AT2G43430 | glyoxalase 2-1 |
Arabidopsis thaliana | AT1G06130 | glyoxalase 2-4 |
Arabidopsis thaliana | AT3G10850 | hydroxyacylglutathione hydrolase |
Babesia bovis | BBOV_IV004560 | hydroxyacylglutathione hydrolase, putative |
Brugia malayi | Bm1_40000 | Chain A, Human Glyoxalase Ii With Cacodylate And Acetate Ions Present In The Active Site. |
Candida albicans | CaO19.4088 | glyoxylase 2 |
Candida albicans | CaO19.11569 | glyoxylase 2 |
Caenorhabditis elegans | CELE_Y17G7B.3 | Protein Y17G7B.3 |
Dictyostelium discoideum | DDB_G0285717 | beta-lactamase domain-containing protein |
Drosophila melanogaster | Dmel_CG4365 | CG4365 gene product from transcript CG4365-RB |
Escherichia coli | b0212 | hydroxyacylglutathione hydrolase |
Echinococcus granulosus | EgrG_000704000 | hydroxyacylglutathione hydrolase |
Echinococcus multilocularis | EmuJ_000704000 | hydroxyacylglutathione hydrolase |
Homo sapiens | 3029 | hydroxyacylglutathione hydrolase |
Leishmania braziliensis | LbrM.12.0240 | hydroxyacylglutathione hydrolase, putative,glyoxalase II, putative |
Leishmania donovani | LdBPK_120200.1 | glyoxalase II, putative |
Leishmania infantum | LinJ.12.0200 | glyoxalase II, putative |
Leishmania major | LmjF.12.0220 | hydroxyacylglutathione hydrolase, putative,glyoxalase II, putative |
Leishmania mexicana | LmxM.12.0220 | hydroxyacylglutathione hydrolase, putative,glyoxalase II, putative |
Loa Loa (eye worm) | LOAG_02231 | hydroxyacylglutathione hydrolase |
Mycobacterium leprae | ML1912 | POSSIBLE GLYOXALASE II (HYDROXYACYLGLUTATHIONE HYDROLASE) (GLX II) |
Mus musculus | ENSMUSG00000024158 | hydroxyacyl glutathione hydrolase |
Mycobacterium tuberculosis | Rv0634c | Possible glyoxalase II (hydroxyacylglutathione hydrolase) (GLX II) |
Mycobacterium ulcerans | MUL_0715 | glyoxalase II, GloB |
Neospora caninum | NCLIV_023550 | hydroxyacylglutathione hydrolase, putative |
Oryza sativa | 4347581 | Os09g0516600 |
Oryza sativa | 4332736 | Os03g0332400 |
Onchocerca volvulus | OVOC5133 | Hydroxyacylglutathione hydrolase, mitochondrial homolog |
Plasmodium berghei | PBANKA_1004000 | cytosolic glyoxalase II, putative |
Plasmodium falciparum | PF3D7_0406400 | cytosolic glyoxalase II |
Plasmodium knowlesi | PKNH_0304400 | cytosolic glyoxalase II, putative |
Plasmodium vivax | PVX_000925 | hydroxyacyl glutathione hydrolase, putative |
Plasmodium yoelii | PY05100 | hypothetical protein |
Saccharomyces cerevisiae | YOR040W | hydroxyacylglutathione hydrolase GLO4 |
Saccharomyces cerevisiae | YDR272W | hydroxyacylglutathione hydrolase GLO2 |
Schistosoma japonicum | Sjp_0078530 | ko:K01069 hydroxyacylglutathione hydrolase [EC3.1.2.6], putative |
Schistosoma mansoni | Smp_091010 | hydroxyacylglutathione hydrolase (Glyoxalase II) (Glx II) |
Schmidtea mediterranea | mk4.000398.04 | Hydroxyacylglutathione hydrolase, mitochondrial |
Schmidtea mediterranea | mk4.058797.00 | Hydroxyacylglutathione hydrolase, mitochondrial |
Schmidtea mediterranea | mk4.000945.09 | Hydroxyacylglutathione hydrolase, mitochondrial |
Trypanosoma brucei gambiense | Tbg972.6.780 | hydroxyacylglutathione hydrolase, putative,glyoxalase II |
Trypanosoma brucei | Tb927.6.1080 | hydroxyacylglutathione hydrolase, putative |
Trypanosoma congolense | TcIL3000_6_540 | hydroxyacylglutathione hydrolase, putative |
Trypanosoma cruzi | TcCLB.509429.290 | hydroxyacylglutathione hydrolase, putative |
Trypanosoma cruzi | TcCLB.507603.230 | hydroxyacylglutathione hydrolase, putative |
Toxoplasma gondii | TGME49_281630 | hydroxyacylglutathione hydrolase |
Theileria parva | TP01_0292 | hydroxyacyl glutathione hydrolase, putative |
Trichomonas vaginalis | TVAG_243530 | beta lactamase domain, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.1080 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.1080 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.1080 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.6.1080 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b0212 | Escherichia coli | non-essential | goodall |
TGME49_281630 | Toxoplasma gondii | Essentiality uncertain | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.6
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Rattus norvegicus | Glyoxalase II | Compounds | References |
Homo sapiens | hydroxyacylglutathione hydrolase | Compounds | References |
Leishmania major | hydroxyacylglutathione hydrolase, putative,glyoxalase II, putative | Compounds | References |
Bos taurus | Hydroxyacylglutathione hydrolase, mitochondrial | Compounds | References |
Type | Source | Notes |
---|---|---|
soluble recombinant protein | Structural Genomics for Pathogenic Protozoa (SGPP) | Tbru016355; Recombinant protein: full-length; Source: T brucei; glyoxalase II ; |
Target | Type | Source | Notes |
---|---|---|---|
Tb927.6.1080 | cloned gene | BRENDA | A gene with this EC number or name or sequence has been cloned from Trypanosoma brucei ( 1 ) |
2 literature references were collected for this gene.